Nadia Demarteau

Summary

Affiliation: GlaxoSmithKline Biologicals
Country: Belgium

Publications

  1. pmc Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada
    Michele Kohli
    OptumInsight, Health Economics and Outcomes Research, 5500 North Service Rd, Burlington, ON L7L 6W6, Canada
    BMC Public Health 12:872. 2012
  2. doi request reprint Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium
    Nadia Demarteau
    Health Economics, GlaxoSmithKline Vaccines, Rue Fleming 20, B 1300 Wavre, Belgium
    Vaccine 31:3962-71. 2013
  3. doi request reprint Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan
    Nadia Demarteau
    GlaxoSmithKline Biologicals, Wavre, Belgium
    Value Health 15:622-31. 2012
  4. doi request reprint Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program
    Nadia Demarteau
    Health Economics, Global Vaccine Development, GlaxoSmithKline Biologicals, Wavre, Belgium
    Pharmacoeconomics 30:337-53. 2012
  5. pmc A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females
    Andrea M Anonychuk
    Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
    BMC Public Health 9:401. 2009
  6. pmc Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models
    Mark Jit
    Modelling and Economics Unit, Health Protection Agency, London, UK
    BMC Med 9:54. 2011
  7. ncbi request reprint Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer
    Nadia Demarteau
    Health Economics, GlaxoSmithKline Biologicals, Av Fleming 20, Wavre, Belgium
    J Med Econ 13:324-38. 2010
  8. pmc A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer
    Nadia Demarteau
    Health Economics, GlaxoSmithKline Biologicals, Wavre, Belgium
    Int J Public Health 56:153-62. 2011
  9. doi request reprint Modelling the effect of conjugate vaccines in pneumococcal disease: cohort or population models?
    Baudouin Standaert
    Health Economics, GlaxoSmithKline Biologicals, Parc de la Noire Epine, B 1300 Wavre, Belgium
    Vaccine 28:G30-8. 2010

Collaborators

  • Baudouin Standaert
  • Chien Jen Chen
  • Philippe Simon
  • Michele Kohli
  • Mark Jit
  • Andrea M Anonychuk
  • Andrea Anonychuk
  • Donna Lawrence
  • Jennifer Haig
  • Elamin Elbasha
  • Jane Kim
  • Gary Ginsberg
  • Naiyana Praditsitthikorn
  • Raymond Hutubessy
  • Edina Sinanovic
  • Chris T Bauch
  • Maraki Fikre Merid
  • Georges Van Kriekinge

Detail Information

Publications9

  1. pmc Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada
    Michele Kohli
    OptumInsight, Health Economics and Outcomes Research, 5500 North Service Rd, Burlington, ON L7L 6W6, Canada
    BMC Public Health 12:872. 2012
    ..In this analysis, the estimated clinical and economic benefit of each of these vaccines was compared in the Canadian setting...
  2. doi request reprint Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium
    Nadia Demarteau
    Health Economics, GlaxoSmithKline Vaccines, Rue Fleming 20, B 1300 Wavre, Belgium
    Vaccine 31:3962-71. 2013
    ..The role of protection against non-HPV-16/18 was also investigated...
  3. doi request reprint Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan
    Nadia Demarteau
    GlaxoSmithKline Biologicals, Wavre, Belgium
    Value Health 15:622-31. 2012
    ....
  4. doi request reprint Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program
    Nadia Demarteau
    Health Economics, Global Vaccine Development, GlaxoSmithKline Biologicals, Wavre, Belgium
    Pharmacoeconomics 30:337-53. 2012
    ..Neither alone can provide 100% protection. Consequently it raises the important question about the most efficient combination of screening at specified time intervals and vaccination to prevent cervical cancer...
  5. pmc A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females
    Andrea M Anonychuk
    Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
    BMC Public Health 9:401. 2009
    ..This study estimates the effectiveness and cost-effectiveness of vaccinating 12-year old Canadian females with an AS04-adjuvanted cervical cancer vaccine. The indirect effect of vaccination, via herd immunity, is also estimated...
  6. pmc Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models
    Mark Jit
    Modelling and Economics Unit, Health Protection Agency, London, UK
    BMC Med 9:54. 2011
    ..To provide information about the feasibility of using such models in a developing country setting, we evaluated models of HPV vaccination in terms of their capacity, requirements, limitations and comparability...
  7. ncbi request reprint Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer
    Nadia Demarteau
    Health Economics, GlaxoSmithKline Biologicals, Av Fleming 20, Wavre, Belgium
    J Med Econ 13:324-38. 2010
    ..Two human papillomavirus (HPV) vaccines are on the market. Based on expected differences in sustained- and cross-protection between the two vaccines, their long-term economic value is modelled and compared for France, Ireland and Italy...
  8. pmc A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer
    Nadia Demarteau
    Health Economics, GlaxoSmithKline Biologicals, Wavre, Belgium
    Int J Public Health 56:153-62. 2011
    ..This study aimed at evaluating the cost-effectiveness of human papillomavirus virus (HPV) vaccination in France, using a generally applicable succinct cohort model...
  9. doi request reprint Modelling the effect of conjugate vaccines in pneumococcal disease: cohort or population models?
    Baudouin Standaert
    Health Economics, GlaxoSmithKline Biologicals, Parc de la Noire Epine, B 1300 Wavre, Belgium
    Vaccine 28:G30-8. 2010
    ....